Yüklüyor......
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
BACKGROUND: The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to investigate the existence of EGFR mutations in carcinoma of esophagogastric...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3278359/ https://ncbi.nlm.nih.gov/pubmed/22252115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-10-14 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|